ACADIA Pharmaceuticals Inc. Stock News

Acadia's Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential. Acadia's financials are robust with ris

Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD,

Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the int

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Albert Kildani -

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

An analyst upgraded Acadia Pharmaceuticals shares today. As a result, investors are bidding the stock up in morning trading.

September hasn't been overly kind to growth stocks. This latest bout of volatility, however, may have created some compelling buying opportunities.

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Acadia Pharmaceuticals (NASDAQ: ACAD) stock price did well on Wednesday even as American equities retreated. The biotech stock jumped to a high of $26.15, much higher than this week's low of $22.95.

Acadia Pharmaceuticals' gains recently disappeared despite the strong launch of Daybue. Poor market conditions are to blame, especially the poor biotech investor sentiment. Daybue's sales in Q2 exceed